Grail Inc. Reports Growth and Positive Trial Results

Grail Inc ( (GRAL) ) has released its Q1 earnings. Here is a breakdown of the information Grail Inc presented to its investors.

Grail Inc. is a healthcare company focused on early cancer detection through advanced technology and clinical studies, aiming to alleviate the global burden of cancer. In its first quarter of 2025, Grail Inc. reported a total revenue of $31.8 million, marking a 19% increase year-over-year, with its Galleri test contributing significantly to this growth. The company also announced positive results from the NHS-Galleri trial, showcasing the test’s effectiveness in cancer detection. Key financial metrics for the quarter included a net loss of $106.2 million, an improvement from the previous year, and an adjusted EBITDA of $(98.7) million, reflecting better financial management. The company’s cash position remains strong at $677.9 million, providing a financial runway into 2028. Looking ahead, Grail Inc. is focused on expanding access to its Galleri test and advancing its multi-cancer early detection capabilities, with plans to submit trial data for regulatory approval and continue its partnerships to enhance test accessibility.